0001104659-16-151944.txt : 20161025 0001104659-16-151944.hdr.sgml : 20161025 20161025163316 ACCESSION NUMBER: 0001104659-16-151944 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161025 FILED AS OF DATE: 20161025 DATE AS OF CHANGE: 20161025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vitae Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001157602 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043567753 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 BUSINESS PHONE: 215-461-2000 MAIL ADDRESS: STREET 1: 502 WEST OFFICE CENTER DR CITY: FORT WASHINGTON STATE: PA ZIP: 19034 FORMER COMPANY: FORMER CONFORMED NAME: Vitae Pharmaceuticals Inc DATE OF NAME CHANGE: 20050118 FORMER COMPANY: FORMER CONFORMED NAME: CONCURRENT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HAYDEN DONALD J JR CENTRAL INDEX KEY: 0001202285 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36617 FILM NUMBER: 161950733 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 4 1 a4.xml 4 X0306 4 2016-10-25 1 0001157602 Vitae Pharmaceuticals, Inc VTAE 0001202285 HAYDEN DONALD J JR C/O VITAE PHARMACEUTICALS, INC. 502 WEST OFFICE CENTER DR. FORT WASHINGTON PA 19034 1 0 0 0 Stock Option (Right to Buy) 5.29 2016-10-25 4 D 0 18182 15.71 D 2024-06-24 Common Stock 18182 0 D Stock Option (Right to Buy) 8.00 2016-10-25 4 D 0 17000 13.00 D 2024-09-23 Common Stock 17000 0 D Stock Option (Right to Buy) 12.43 2016-10-25 4 D 0 10000 8.57 D 2025-05-27 Common Stock 10000 0 D Stock Option (Right to Buy) 9.62 2016-10-25 4 D 0 10000 11.38 D 2026-05-25 Common Stock 10000 0 D Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated September 13, 2016, by and among the Issuer, Allergan Holdco US, Inc. and Augusta Merger Sub, Inc., each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $21.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. This option, which is fully vested, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. This option, which provided for vesting in three equal annual installments following on September 24, 2014, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. This option, which is fully vested was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. This option, which provided for vesting in four (4) equal quarterly installments following May 26, 2016, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (1) above. /s/ Donald J. Hayden, Jr. 2016-10-25